Oscar Health Inc (OSCR) stock price falls 5.41% to $14.52 on July 17, with a 38.97% decline from its 52-week high. Analysts forecast an average target price of $13.44, with a high estimate of $21.00 and a low estimate of $8.00.

Shares of Oscar Health Inc (OSCR) fell 5.41% to $14.52 on July 17, with a trading volume of 25,199,076 shares, 111.6% of the average daily volume. Analysts forecast an average target price of $13.44, implying a 7.45% downside from the current price. The estimated GF Value is $14.67, suggesting a 1.03% upside. The average brokerage recommendation is 3.1, indicating "Hold" status.

Shares of Oscar Health Inc. (OSCR) experienced a significant decline on July 17, falling 5.41% to $14.52. The trading volume surged to 25,199,076 shares, which was 111.6% of the average daily volume. Analysts have forecasted an average target price of $13.44, implying a potential downside of 7.45% from the current price. The estimated GF Value is $14.67, suggesting a possible upside of 1.03%. The average brokerage recommendation is 3.1, indicating a "Hold" status for investors [1].

The recent downward trend in Oscar Health's stock can be attributed to various factors, including analyst downgrades and a challenging earnings outlook. In the latest quarter, four analysts provided ratings for OSCR, with a mix of bullish and bearish perspectives. The Zacks Consensus EPS estimate has moved 5.98% lower over the past 30 days, and the company currently possesses a Zacks Rank of #4 (Sell) [2]. This rank suggests a cautious outlook on the part of analysts.

Oscar Health's financial performance has been a subject of interest, with notable growth in revenue and strong net margins. However, the company's market capitalization has fallen below industry benchmarks, reflecting reduced size compared to peers. The company's debt-to-equity ratio is below the industry average, indicating a healthier balance between debt and equity [2].

Analysts have also adjusted their price targets, with the current average target of $14.00 representing a 25.01% decrease from the previous average of $18.67. Key analysts such as Jonathan Yong of UBS, Stephen Baxter of Wells Fargo, and Andrew Mok of Barclays have lowered their ratings and price targets, reflecting a bearish sentiment [2].

In conclusion, the recent performance of Oscar Health Inc. (OSCR) has been influenced by a combination of analyst downgrades and financial metrics. While the company has shown strong revenue growth and efficient cost management, the overall outlook remains cautious, with analysts recommending a "Hold" status. Investors should closely monitor the upcoming earnings release and any changes in analyst estimates for further insights into the company's future prospects.

References:
[1] https://finance.yahoo.com/news/oscar-health-inc-oscr-surpasses-220004910.html
[2] https://www.nasdaq.com/articles/what-analysts-are-saying-about-oscar-health-stock